Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 13, Pages 5334-5348Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01538
Keywords
-
Categories
Funding
- COST Action (Epigenetic Chemical Biology EPICHEMBIO) [CM1406]
- Deutsche Forschungsgemeinschaft (DFG) [Ju295/13-1]
- Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe
- Medical Faculty HHU Duesseldorf
- Centre National de la Recherche Scientifique (CNRS)
- Institute National de la Sante et de la Recherche Medicale (INSERM)
- Universite de Strasbourg
- Deutsche Forschungsgemeinschaft (DFG)
Ask authors/readers for more resources
The synthesis and biological evaluation of potent hydroxamate-based dual HDAC1/6 inhibitors with modest HDAC6 preference and a novel alkoxyurea connecting unit linker region are described. The biological studies included the evaluation of antiproliferative effects and HDAC inhibitory activity in the human ovarian cancer cell line A2780, the human squamous carcinoma cell line Cal27, and their cisplatin resistant sublines A2780CisR and Cal27CisR. The three most potent compounds 1gi showed IC50 values in the low mu M and sub-mu M range. 1gi revealed low nM IC50 values for HDAC6 with up to 15-fold preference over HDAC1, >3500-fold selectivity over HDAC4, and >100-fold selectivity over HDAC8. Furthermore, their ability to enhance cisplatin sensitivity was analyzed in Cal27 and Cal27CisR cells. Notably, a 48 h preincubation of 1-gi significantly enhanced the antiproliferative effects of cisplatin in Cal27 and Cal27CisR. 1-gi interacted synergistically with cisplatin. These effects were more pronounced for the cisplatin resistant subline Cal27CisR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available